BACKGROUND A direct comparison of outcomes between moderate mixed aortic valve disease (MAVD) and isolated
T
here is a paucity of data regarding the natural history of combined aortic stenosis (AS) and aortic regurgitation (AR), making evidence-based recommendations regarding aortic valve replacement (AVR) in this subgroup of patients challenging (1) (2) (3) (4) (5) . In the absence of guideline-directed recommendations for mixed aortic valve disease (MAVD), clinicians often base their decisions on the recommendation for the predominant lesion (2, 3, 5, 6) .
For isolated severe AS or AR, AVR is generally recommended in the setting of symptoms, left ventricular (LV) systolic dysfunction, or progressive LV dilation (2, 3, 5) . Conversely, isolated moderate AS or moderate AR has a benign prognosis, and as a result, the recommended strategy is conservative management (5, 7, 8) .
The limited available data on MAVD suggest an aggressive disease course in this population that differs from that of isolated moderate AS or AR (1, 4) . However, a direct comparison of outcomes between MAVD and isolated AS or AR has not been performed.
Our hypothesis was that patients with moderate MAVD had similar outcomes to those with asymptomatic severe AS and preserved ejection fraction and, therefore, should be managed as such.
METHODS
A retrospective study of asymptomatic patients (New York Heart Association [NYHA] functional class I, age >18 years) with MAVD followed at Mayo Clinic be- Patients with radiation-induced valvular heart disease, prior endocarditis, prior aortic valve intervention, or coexistent valvular heart disease (defined as moderate or greater stenosis or regurgitation of the mitral, tricuspid, or pulmonary valves) were excluded.
MVAD patients were compared with 3 control groups matched by age (AE 5 years) and sex. The first control group comprised patients with isolated moderate AR, the second group patients with isolated moderate AS, and the third group patients with isolated severe AS. Similar to the MAVD cohort, the control groups were asymptomatic and had normal LV function at the beginning of this study.
The control groups were selected from all patients with aortic valve disease followed at Mayo Clinic within the study period. Although there were 251 MAVD patients in the study, only 117 of them had ageand sex-matched control subjects identified in the electronic medical records. To ensure equal numbers of patients in each group, only 117 MAVD patients were included in the comparative analysis.
The primary endpoint was to determine composite adverse event (AE) occurrence, defined as the development of NYHA functional class III or IV symptoms (angina, exertional dyspnea, exertional syncope, or pre-syncope), AVR, or cardiac death (death directly related to cardiac pathology such as congestive heart failure, myocardial infarction, or sudden death). The secondary endpoint was to compare AE rate between the MAVD cohort and the control groups. For AE, only 1 event (the earliest event) was counted per patient.
The patients were followed (remained at risk) until the occurrence of primary endpoint, noncardiac death, loss of follow-up defined as no clinic follow-up in 2 years, or at the end of the study period. The Mayo Clinic Institutional Review Board approved this study protocol.
AORTIC VALVE DISEASE SEVERITY CLASSIFICATION.
According to published guidelines (2,5,9,10), moderate AS was defined as peak velocity 3.0 to 3.9 m/s and valve area 1.1 to 1. The AE rates for the MAVD cohort and the control groups were assessed using the Kaplan-Meier method and compared using the log-rank test. The "time-0" or beginning of the "at-risk period" was defined as the time of initial diagnosis of MAVD or isolated valve disease. Only patients who had not reached the primary endpoint, noncardiac death, or loss of follow-up were censored at each time point on the Kaplan-Meier analysis. All p values were 2-sided, and p values <0.05 were considered significant.
RESULTS
We followed 251 patients (mean age 63 AE 11 years; 184
[73%] males) with moderate MAVD for 9.1 AE 4.2 years, including 97 (38%) with bicuspid valve and 39 (16%) with coronary artery disease ( Table 1) . At the time of AVR, 24 patients (14%) had progressed to symptomatic severe AR, with LV enddiastolic and -systolic dimensions of 58 AE 6 mm and 42 AE 3 mm, respectively ( Table 2) .
There were 19 patients (11%) who underwent AVR due to symptom development in the absence of progression to severe aortic valve disease ( Table 2) .
Seventeen of these patients underwent exercise testing, and all 17 patients had abnormal findings including electrocardiographic changes, symptoms (angina and exertional dyspnea), or abnormal blood There were 19 deaths (9 cardiac, 8 noncardiac, and 2 unknown) reported during the study period. A total of 10 of these deaths occurred in the AVR arm; 1 occurred perioperatively, with the others due to: congestive
, and unknown cause (n ¼ 1). A total of 9 deaths occurred in the non-AVR arm and the causes were: congestive heart failure Table 3) .
MAVD COHORT AND CONTROL GROUPS AND OUTCOMES.
A total of 117 patients with moderate MAVD were Values are mean AE SD.
Abbreviations as in Table 1 .
Egbe et al. Table 4 ).
In the MAVD cohort, the occurrence of NYHA functional class III/IV symptoms was 38% (95% CI:
34% to 42%), 62% (95% CI: 56% to 69%), and 73% (95% CI: 64% to 82%); the occurrence of AVR was 37% (95% CI: 34% to 40%), 65% (95% CI: 57% to 74%), and 76% (95% CI: 69% to 85%); and the occurrence of composite AE was 40% (95% CI: 36% to 44%), 71%
(95% CI: 61% to 79%), and 84% (95% CI: 73% to 91%), at 3, 5, and 7 years, respectively.
The composite AE rate in the moderate MAVD cohort was similar to the severe AS group (71% vs.
68% at 5 years; p ¼ 0.49) but was significantly higher than the moderate AS group (71% vs. 31% at 5 years; p < 0.0001) and the moderate AR group (71% vs. 22% at 5 years; p < 0.0001) ( Table 5 , Central Illustration).
DISCUSSION
The purpose of this study was to determine the outcomes in moderate MAVD and compare these outcomes to matched cohorts with isolated AS or AR.
This is the largest study reporting outcomes specifically in patients with moderate MAVD, and it showed that the prevalence of AE was 40%, 71%, and 84% at 3, 5, and 7 years, respectively. The risk factors for AE were older age and increased LV mass, but not the presence of an underlying bicuspid valve. Values are n (%) or mean AE SD. *Comparison of MAVD and severe aortic stenosis. †Concomitant CABG and aorta replacement calculated as percentage of AVR in each subset.
AR ¼ aortic regurgitation; AS ¼ aortic stenosis; other abbreviations as in Table 1 . or cardiac death) rate of 81% at 6 years. Aortic peak velocity was predictive of AE in that series. Apart from a younger patient age (mean age 52 years), the patient demographics and comorbidities were comparable to our cohort. An important difference is that more than two-thirds of that cohort had severe AS or AR at the beginning of the study period.
The second study was a retrospective analysis of 524 patients with MAVD (4), specifically, mild or worse AS plus mild or worse AR. Results showed that 67% of patients required AVR within 4 years and that the risk factors for AE (AVR and death) were older age and increased LV mass at the time of presentation, similar to our findings. One important difference:
moderate MAVD comprised less than one-quarter of the study's cohort.
The results of these 2 prior investigations were concordant; both studies suggested that MAVD was associated with higher AE rates compared with historical cohorts of isolated AS or AR. However, the majority of both cohorts already had severe AS or AR at the beginning of the study; as a result, the high event rates reported in these studies were not unexpected.
The outcomes of moderate MAVD are unknown;
subsequently, there are no guideline recommendations for the timing of intervention or the frequency of follow-up in this population (2, 3, 5) . A common practice is to extrapolate from guideline recommendations for the predominant lesion (6) , which in this case, is either moderate AS or moderate AR. The AE rates for moderate AS have been reported at approximately 25% to 30% at 3 years (13-15), but it is much lower for isolated AR (7, 16) . Because of the low event rates for moderate AS or moderate AR, the current guidelines recommend conservative management and follow-up every 1 to 2 years to monitor for progression of valve disease in this population (2, 5 ).
The current study shows an AE rate of 71% at 5 years, which was significantly higher compared with control subjects with moderate AS (31% at 5 years), control subjects with moderate AR (22% at 5 years), or historical cohorts of moderate AS (13) (14) (15) . An important observation from the current study was that the event rates in those with moderate MAVD were similar to that of a matched cohort with isolated severe AS (peak velocity 4.0 to 4.9 m/s) and historical cohorts of isolated AS (peak velocity 4.0 to 4.9 m/s) (17, 18) .
PROGRESSION OF AS.
The predominant mechanism of progression of valve disease in this study was the progression of stenosis. The aortic peak velocity and mean gradient increased by 0.38 AE 0.24 m/s/year and 7 AE 4 mm Hg/year, respectively, in our cohort.
Concordant with the increase in peak velocity and gradient over time, the valve area also decreased, suggesting that the observed increased velocity was not just from increased stroke volume due to worsening AR.
The rate of progression of aortic valve disease has been reported as 0.32 to 0.41 m/s/year in prior series of asymptomatic severe AS (13, 17, 19) and 0.24 m/s/year in a moderate AS cohort (14) . The rate of progression in our cohort was similar to that of severe AS. The annual rate of increase in aortic peak velocity has been shown to be predictive of AE (13, 14, 19) and may account for the similarity in the occurrence of AE in our cohort compared with isolated severe AS.
PROGRESSION OF AR.
Another mechanism for the progression of valve disease in this study was progression of regurgitation. An interesting observation was that none of the 24 (14%) patients who developed symptomatic severe AR achieved an LV end-systolic dimension of 50 mm at the time of AVR, although that is the threshold for recommending AVR for AR (2, 5) . This also was not observed in 2 prior studies of Values are n (%). *Only 1 event was counted for each patient.
NYHA ¼ New York Heart Association; other abbreviations as in Tables 1 and 4 .
of our speculation, Honda et al. (21) showed that concomitant AR in the setting of AS was predictive of symptoms, hospitalization, and all-cause mortality.
STUDY LIMITATIONS. First, the retrospective nature of this study, using a cohort from a single tertiary center, may have resulted in some selection bias. However, any bias introduced by underestimation of mortality in MAVD patients will be balanced by similar underestimation in the control groups.
CONCLUSIONS
The AE outcomes in moderate MAVD appeared to be similar to those with asymptomatic isolated severe AS with preserved LV systolic function. This suggests that it would be inappropriate to apply guideline recommendations for isolated moderate AS or moderate AR to this population. Additionally, a subset of moderate MAVD patients with concentric hypertrophy can become symptomatic even in the absence of severe aortic valve disease.
On the basis of these findings, we recommend that patients with moderate MAVD be followed every 6 to 12 months and monitored closely for rapid progression of valve disease or development of symptoms, similar to patients with isolated severe AS. Early valve replacement may be considered for MAVD patients without comorbidities in centers with low risk for such procedures.
